Financial Performance - The company reported a basic earnings per share of 0.1294 yuan for 2024, an increase of 16.79% compared to 0.1108 yuan in 2023 [1] - The total revenue for 2024 was 23.71 billion yuan, reflecting a growth of 9.06% from 21.74 billion yuan in 2023 [1] - The net profit for 2024 reached 1 billion yuan, up by 16.28% from 0.86 billion yuan in 2023 [1] - The return on equity (ROE) improved to 4.50% in 2024, compared to 3.88% in 2023, marking a 15.98% increase [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 33,877.83 million shares, accounting for 45.47% of the circulating shares, with an increase of 317.20 million shares from the previous period [1] - Inner Mongolia Jinhe Holdings Co., Ltd. remains the largest shareholder with 24,175.87 million shares, representing 32.45% of the total share capital, unchanged from the previous report [2] - New entrants in the top ten shareholders include Shenzhen Zetun Private Securities Fund Management Co., Ltd. and Baosheng Mixed Fund A, with holdings of 535.37 million shares and 414.06 million shares respectively [2] Dividend Distribution - The company announced a dividend distribution plan of 1 yuan per share (including tax) [2]

作为公司独立董事，本人未在公司兼任除董事会专门委员会召集人或者委员 以外的其他职务，与公司及其控股股东不存在可能妨碍本人进行独立客观判断的 关系，本人独立履行职责，不受公司控股股东或者其他与公司存在利害关系的单 位或个人的影响。本人具备《上市公司独立董事管理办法》《深圳证券交易所股 票上市规则》所要求的独立性，并按照监管规则进行了独立性自查，不存在影响 独立性的情况。 金河生物科技股份有限公司 2024 年度独立董事述职报告 本人作为金河生物科技股份有限公司（以下简称"金河生物"、"公司"） 独立董事，任职期间严格按照《中华人民共和国公司法》《上市公司独立董事管 理办法》等法律、法规以及《公司章程》《独立董事制度》等有关规定，认真履 行职责，积极的参加公司相关会议，认真审议董事会各项议案，对相关事项发表 了独立意见，充分发挥独立董事的独立性和专业性作用，切实维护公司及全体股 东尤其是中小股东的合法权益。现将 2024 年度履行独立董事职责汇报如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 卢文兵：1967 年出生，中国籍，无境外居留权。研究生学历。现任内蒙古民 丰种业有限公司董事长，内蒙古腾格里投资 ...

关于独立董事独立性情况的专项意见 金河生物科技股份有限公司董事会 关于独立董事独立性情况的专项意见 1 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等要求，金河生物科技股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事郭晓川先生、卢文兵先生、谢晓 燕女士的独立性情况进行核查、评估并出具如下专项意见： 经核查独立董事郭晓川先生、卢文兵先生、谢晓燕女士的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况。因此， 公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 金河生物科技股份有限公司 董 事 会 2025 年 4 月 25 日 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,370,626,965.11, representing a 9.04% increase compared to ¥2,174,131,033.42 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥100,200,680.03, marking a 15.90% increase from ¥86,457,012.48 in 2023[6]. - The cash flow from operating activities for 2024 surged to ¥498,423,937.19, a significant increase of 150.76% from ¥198,765,852.62 in 2023[6]. - The basic earnings per share for 2024 was ¥0.1294, up 16.79% from ¥0.1108 in 2023[6]. - The total assets at the end of 2024 amounted to ¥5,650,587,583.04, reflecting a 3.61% increase from ¥5,453,807,416.04 at the end of 2023[6]. - The veterinary chemical drug segment generated revenue of 1,234.27 million yuan, a year-on-year increase of 21.47%, accounting for 52.06% of total revenue[59]. - The gross margin for veterinary chemical drugs improved to 40.17%, an increase of 7.40 percentage points from the previous year[59]. - The company achieved a revenue of 2,370.63 million yuan in 2024, representing a year-on-year growth of 9.04%[57]. - Net profit attributable to shareholders increased to 100.20 million yuan, up by 15.90% compared to the previous year[57]. - The veterinary biological products segment achieved revenue of 343.68 million yuan, a year-on-year increase of 2.58%, while the cost of goods sold increased by 27.45%[67]. Market Expansion and Strategy - The company is expanding its market presence, with a focus on both domestic and international markets, including key regions like the United States, Canada, and Southeast Asia[47]. - Future growth is anticipated in the veterinary vaccine sector, which is expected to become a high-growth area for the company[41]. - The company aims to enhance its R&D capabilities to meet the urgent demand for new products and technologies in the veterinary industry[29]. - The company is actively pursuing market expansion strategies, including potential acquisitions to strengthen its portfolio[109]. - The company plans to continue investing in R&D to enhance its core competitiveness despite the decrease in capitalized R&D expenditures[99]. - The company is focusing on expanding its pet medication product line to capitalize on the growing pet economy[152]. - The company plans to enhance its vaccine production capacity at the Jilin facility, with a planned capacity of 200 million doses, up from the current 100 million doses[75]. - The company is strategically developing an African swine fever vaccine in collaboration with well-known research institutions, indicating a significant market opportunity[74]. Research and Development - The company is focusing on R&D innovation, with several new vaccines and products in the pipeline, including a new inactivated vaccine for pigs and a new vaccine for cattle[68]. - The company is developing a new vaccine for African swine fever, expected to receive a new veterinary drug certificate by December 2026[97]. - The company is in the laboratory research phase for a new bovine respiratory disease vaccine, with a broad application prospect[97]. - The company is working on a dual inactivated vaccine for swine fever and pseudorabies, with registration expected after several trials[98]. - The company is developing a four-in-one inactivated vaccine for cats, with a market outlook from July 2024 to June 2029[98]. - The company has established two major R&D centers for animal vaccines, enhancing its global R&D capabilities and fostering innovation in vaccine development[51]. - The company is investing in vaccine R&D despite the long cycles and high costs, recognizing the inherent uncertainties in the outcomes[156]. Corporate Governance and Management - The company emphasizes that the operational plans and targets for 2025 and beyond are planning matters and do not constitute a substantive commitment to investors, highlighting the need for risk awareness[4]. - The company has established a comprehensive information disclosure system, ensuring that all relevant financial documents are available to stakeholders[15]. - The company maintains independence from its controlling shareholders, ensuring autonomous operations[164]. - The company has established an independent financial department and internal audit department, ensuring no shared bank accounts with controlling shareholders[169]. - The company has a complete and independent business system, with no reliance on shareholder assets for operations[170]. - The board of directors convened 12 meetings, maintaining effective governance and oversight[165]. - The supervisory board met nine times, ensuring compliance and protecting shareholder interests[165]. - The company held three shareholder meetings during the reporting period, ensuring compliance with legal requirements[163]. Production and Capacity - The company has increased its production capacity by 60,000 tons, equivalent to a 15% increase in the production of the core product, the chlortetracycline premix[39]. - The production capacity for the main product, Chlortetracycline, is currently 55,000 tons/year, with a new project expected to add an additional 60,000 tons/year, significantly enhancing production capacity[55]. - The company has established four production bases and two research centers, enhancing its competitive edge in the animal health industry[40]. - The company's new intelligent factory is expected to reduce production costs and improve fermentation efficiency, strengthening market competitiveness[39]. Financial Management - The company reported a significant increase in the gross margin of corn starch sales despite a decline in sales volume due to lower corn prices, contributing to higher overall profitability[78]. - The company reported an increase in interest expenses due to a rise in interest-bearing liabilities[57]. - The total procurement amount from the top five suppliers was ¥258,196,423.96, representing 15.67% of the annual procurement total[93]. - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, protecting investors' interests[132]. - The company has implemented strict approval procedures for expenditures related to the raised funds[132]. Risks and Challenges - The company acknowledges risks from downstream industry fluctuations, particularly in the livestock sector, which directly impacts revenue[156]. - The company faces risks from rising raw material and energy prices, which could affect profit margins on veterinary chemical products[156]. - The company is addressing the complexities of the international trade environment, which may increase export costs and impact operations[157]. Employee and Training - The total number of employees at the end of the reporting period is 2,476, with 1,299 in the parent company and 1,177 in major subsidiaries[197]. - The company conducted 121 internal training sessions throughout the year, with approximately 8,863 participants, focusing on operational procedures, GMP regulations, and EHS knowledge[200]. - The company has established a comprehensive salary system based on regional salary levels and its own characteristics, combining basic salary and performance-based pay[199]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 36.01% on May 20, 2024, indicating active shareholder engagement[171]. - The first extraordinary shareholders' meeting of 2024 had a participation rate of 38.49% on August 6, 2024, reflecting continued investor interest[171]. - The company has implemented a share repurchase program, with a focus on restricted stock incentives[172].

Financial Performance - The company's revenue for Q1 2025 was CNY 625,145,364.48, representing a 20.35% increase compared to CNY 519,450,050.36 in the same period last year[4]. - Net profit attributable to shareholders was CNY 51,116,537.85, up 13.23% from CNY 45,143,153.81 year-on-year[4]. - Basic and diluted earnings per share increased by 14.53% to CNY 0.0662, compared to CNY 0.0578 in the same period last year[4]. - Net profit for the current period was ¥51,782,589.64, representing a 9.3% increase from ¥47,574,039.07 in the previous period[23]. - Earnings per share (EPS) for the current period was ¥0.0662, compared to ¥0.0578 in the previous period, reflecting a growth of 14.9%[23]. - The company reported a total comprehensive income of ¥50,939,813.63 for the current period, compared to ¥46,785,956.65 in the previous period, an increase of 8.6%[23]. Cash Flow - The net cash flow from operating activities decreased by 21.22% to CNY 57,819,950.74, down from CNY 73,390,050.46 in the previous year[4]. - Operating cash flow for the current period is ¥57,819,950.74, a decrease of 21.2% from ¥73,390,050.46 in the previous period[24]. - Total cash inflow from operating activities is ¥593,282,261.11, compared to ¥571,501,441.52 in the previous period, reflecting a growth of 3.1%[24]. - Cash outflow from operating activities increased to ¥535,462,310.37 from ¥498,111,391.06, representing a rise of 7.5%[24]. - Investment activities generated a net cash flow of -¥67,865,040.40, an improvement from -¥83,274,179.55 in the previous period[24]. - Net cash flow from financing activities decreased by CNY 105,384,328.70, a decline of 95.27%, as operating cash flow was sufficient to meet the company's normal operational needs, reducing bank borrowings[13]. - Net cash flow from financing activities was ¥5,230,846.58, significantly lower than ¥110,615,175.28 in the previous period, a decline of 95.3%[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,682,049,224.10, a slight increase of 0.56% from CNY 5,650,587,583.04 at the end of the previous year[4]. - Total assets as of the end of the current period were ¥5,682,049,224.10, slightly up from ¥5,650,587,583.04 in the previous period[21]. - Total liabilities decreased to ¥3,123,997,855.14 from ¥3,150,724,813.22, indicating a reduction of 0.8%[21]. - The total equity attributable to shareholders of the parent company increased to ¥2,303,056,809.68 from ¥2,246,607,845.93, marking a growth of 2.5%[21]. Expenses - Total operating costs amounted to ¥569,770,727.13, up 21.3% from ¥469,749,153.26 in the prior period[22]. - Management expenses increased by 49.28% to CNY 25,664,246.52, mainly due to salary adjustments and legal fees for tax refund assistance[7]. - Research and development expenses for the current period were ¥22,598,102.58, up from ¥19,538,556.28, reflecting an increase of 10.5%[22]. Investments - Investment income rose by 118.04% to CNY 571,820.19, mainly from interest on debt investments by a subsidiary[8]. - The company reported a decrease in long-term equity investments to CNY 259,204.80 from CNY 259,573.12, suggesting stability in investment holdings[19]. - The company received ¥1,200,000.00 from minority shareholders as part of investment activities[24]. - Cash received from other financing activities increased to ¥63,184,715.90 from ¥50,000,000.00, a growth of 26.4%[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 31,569, with no preferred shareholders[15]. - The largest shareholder, Inner Mongolia Jinhe Holdings Co., Ltd., holds 31.33% of shares, totaling 241,758,670 shares[15]. Inventory and Receivables - Accounts receivable increased to CNY 543,379,584.90 from CNY 498,611,653.92, indicating a rise in credit sales[19]. - Inventory at the end of the reporting period was CNY 666,182,132.79, up from CNY 635,279,943.82, reflecting increased stock levels[19]. Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 159.60% to CNY 28,284,968.40, primarily to ensure sufficient supply of raw materials[6]. - The company experienced a 60.92% increase in taxes and surcharges, amounting to CNY 2,227,076.54, attributed to improved operational performance[7]. - The company reported a 51.13% decrease in tax refunds received, totaling CNY 15,891,497.15, due to the absence of customs duty refunds this period[11]. - Deferred income tax assets decreased to ¥51,963,930.59 from ¥71,211,031.61, a decline of 26.9%[20]. Audit Information - The company did not undergo an audit for the first quarter report[26].

截至4月24日收盘，宠物经济概念上涨1.74%，位居概念板块涨幅第4，板块内，49股上涨，天元宠物 20%涨停，中宠股份、依依股份等涨停，乖宝宠物、路斯股份、科拓生物等涨幅居前，分别上涨 15.44%、14.74%、11.58%。跌幅居前的有海能技术、海昇药业、祖名股份等，分别下跌5.87%、 4.97%、3.56%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | PEEK材料 | 3.70 | 电子身份证 | -3.20 | | 丙烯酸 | 1.89 | 华为盘古 | -3.13 | | 天津自贸区 | 1.75 | 数字货币 | -3.10 | | 宠物经济 | 1.74 | 数据安全 | -3.07 | | 维生素 | 1.35 | 云办公 | -2.98 | | 阿尔茨海默概念 | 1.30 | 智谱AI | -2.98 | | NMN概念 | 1.22 | 数据确权 | -2.94 | | 人造肉 | 1.06 | 智慧政务 | -2.92 | | CRO概念 | 0.96 | 华为鲲鹏 | -2 ...

Investment Rating - The report maintains a "Recommended" investment rating for the industry, suggesting a potential upside of over 15% relative to benchmark indices [4]. Core Insights - The swine industry shows stable breeding profits, with a focus on capacity reduction logic. The average price of external three yuan pigs was 15.0 CNY/kg, up 2.1% week-on-week, while the average weight of pigs sold was 128.6 kg, down 0.2% [19][20]. - The beef industry is at an inflection point, with strong price performance continuing. The average price of calves was 28.2 CNY/kg, up 2.1%, and the average price of fattened cattle was 25.8 CNY/kg, up 0.7% [23][30]. - The white chicken market is affected by ongoing avian influenza, with significant impacts on breeding stock and prices. The average price of white feather broiler chicks was 2.8 CNY/chick, up 9.5% [31][34]. - The animal health sector is seeing a recovery in demand as breeding supply stabilizes, with a notable increase in the issuance of vaccines [48][49]. Summary by Sections Swine Industry - The average price of external three yuan pigs was 15.0 CNY/kg, reflecting a week-on-week increase of 2.1%. The average weight of pigs sold was 128.6 kg, down 0.2%. The price of 15 kg external three yuan piglets was 668 CNY/head, with a slight decrease of 0.05% [19][21]. - Supply pressure remains stable, with normal sales rhythms from large producers and limited sales from smallholders. The demand side shows increased activity from secondary breeding, but overall consumption remains weak [20][21]. - The report recommends companies such as Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe for investment [20]. Beef Industry - The beef breeding industry is entering a capacity release phase, with the earliest signs of a price bottom forming. The report anticipates a potential recovery in the industry by late 2025 or early 2026 [23][30]. - The average wholesale price of beef was 61.4 CNY/kg, reflecting a slight increase of 0.2% [29][30]. - Recommended companies include Fucheng Co. and Guangming Meat Industry, focusing on integrated breeding and sales [23]. Poultry Industry - The average price of white feather broiler eggs was 1.6 CNY/egg, up 2.0%, while the average price of white feather broilers was 3.7 CNY/kg, up 2.2% [31][34]. - The report highlights the impact of avian influenza on breeding imports, particularly from the U.S. and New Zealand, which has been suspended for over three months [31][32]. - Recommended companies include Yisheng Livestock and He Feng Food [31]. Animal Health Sector - The demand for animal health products is expected to recover as breeding supply stabilizes. The issuance of vaccines has shown significant increases, particularly for swine diseases [48][49]. - The report recommends companies like Kexin Biological and Zhongmu Biotechnology, which are positioned to benefit from the recovery in the animal health market [49].

证券代码：002688 证券简称：金河生物 公告编号：2025-015 金河生物科技股份有限公司 第六届董事会第二十四次会议决议公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、误导性陈述或者重 大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）第六届董事会第二十四次会议于2025年4月9日以电子邮 件方式发出通知，并于2025年4月18日以通讯方式召开，会议由董事长王东晓先生主持，应到董事9人， 实到董事9人，本次董事会出席会议董事人数符合法律法规，会议合法有效。会议召开符合《中华人民 共和国公司法》等法律、法规和《公司章程》的规定。与会董事以通讯表决的方式审议通过了以下议 案： 一、以9票同意，0票反对，0票弃权审议通过了《关于变更公司注册资本及修订〈公司章程〉部分条款 的议案》。 本议案需提交2025年第二次临时股东大会审议。 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）及《证券时报》、《中国证券报》、 《证券日报》和《上海证券报》披露的《关于变更公司注册资本及修订〈公司章程〉部分条款的公 告》，修订后的《公司章程》详见巨 ...

金河生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 第六届董事会第二十四次会议，审议通过了《关于变更公司注册资本及修订<公 司章程>部分条款的议案》。现将具体情况公告如下： 一、修订《公司章程》和注册资本变更说明 证券代码：002688 证券简称：金河生物 公告编号：2025-016 金河生物科技股份有限公司 关于变更公司注册资本及修订《公司章程》部分条款的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 除上述条款修订外，《公司章程》其他内容不变，本议案尚需提交公司股东 大会审议，公司董事会提请股东大会授权公司管理层或其授权代表办理工商变更 登记、备案等事宜，具体变更内容以工商登记机关核准的内容为准。修订后的《公 司章程》全文详见巨潮资讯网。 鉴于公司第六届董事会第十八次会议、第六届监事会第十五次会议及 2024 年第二次临时股东大会分别审议通过了《关于回购注销部分限制性股票的议案》。 公司 2023 年限制性股票激励计划首次授予激励对象中 1 人因退休离职，已不符 合激励对象条件，公司拟回购注销激励对象已获授 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-017 金河生物科技股份有限公司 关于召开 2025 年第二次临时股东大会通知的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、会议召集人：金河生物科技股份有限公司（以下简称"公司"）董事 会 3、会议召开的合法、合规性：公司于 2025 年 4 月 18 日召开了第六届董 事会第二十四次会议，会议决定于 2025 年 5 月 6 日召开公司 2025 年第二次临 时股东大会。本次股东大会的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》等的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 5 月 6 日下午 14:30 （2）网络投票时间：2025 年 5 月 6 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 6 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证 券交易所互联 ...